1. Market Research
  2. > Cardiovascular Disease – Pipeline Review, H1 2013

Cardiovascular Disease – Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 553 pages

Cardiovascular Disease – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Cardiovascular Disease - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cardiovascular Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiovascular Disease. Cardiovascular Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cardiovascular Disease.
- A review of the Cardiovascular Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cardiovascular Disease pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cardiovascular Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cardiovascular Disease pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Cardiovascular Disease - Pipeline Review, H1 2013
Table of Contents
Table of Contents 2
Introduction 11
Cardiovascular Disease Overview 12
Therapeutics Development 13
Cardiovascular Disease Therapeutics under Development by Companies 15
Cardiovascular Disease Therapeutics under Investigation by Universities/Institutes 35
Late Stage Products 41
Mid Clinical Stage Products 42
Early Clinical Stage Products 43
Discovery and Pre-Clinical Stage Products 44
Cardiovascular Disease Therapeutics - Products under Development by Companies 45
Cardiovascular Disease Therapeutics - Products under Investigation by Universities/Institutes 75
Companies Involved in Cardiovascular Disease Therapeutics Development 81
Cardiovascular Disease - Therapeutics Assessment 290
Drug Profiles 298
Cardiovascular Disease Therapeutics - Drug Profile Updates 392
Cardiovascular Disease Therapeutics - Discontinued Products 482
Cardiovascular Disease Therapeutics - Dormant Products 495
Cardiovascular Disease - Product Development Milestones 531
Appendix 542

List of Tables

Number of Products Under Development for Cardiovascular Disease, H1 2013 23
Products under Development for Cardiovascular Disease - Comparative Analysis, H1 2013 24
Number of Products under Development by Companies, H1 2013 26
Number of Products under Development by Companies, H1 2013 (Contd..1) 27
Number of Products under Development by Companies, H1 2013 (Contd..2) 28
Number of Products under Development by Companies, H1 2013 (Contd..3) 29
Number of Products under Development by Companies, H1 2013 (Contd..4) 30
Number of Products under Development by Companies, H1 2013 (Contd..5) 31
Number of Products under Development by Companies, H1 2013 (Contd..6) 32
Number of Products under Development by Companies, H1 2013 (Contd..7) 33
Number of Products under Development by Companies, H1 2013 (Contd..8) 34
Number of Products under Development by Companies, H1 2013 (Contd..9) 35
Number of Products under Development by Companies, H1 2013 (Contd..10) 36
Number of Products under Development by Companies, H1 2013 (Contd..11) 37
Number of Products under Development by Companies, H1 2013 (Contd..12) 38
Number of Products under Development by Companies, H1 2013 (Contd..13) 39
Number of Products under Development by Companies, H1 2013 (Contd..14) 40
Number of Products under Development by Companies, H1 2013 (Contd..15) 41
Number of Products under Development by Companies, H1 2013 (Contd..16) 42
Number of Products under Development by Companies, H1 2013 (Contd..17) 43
Number of Products under Development by Companies, H1 2013 (Contd..18) 44
Number of Products under Investigation by Universities/Institutes, H1 2013 46
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 47
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 48
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 49
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 50
Comparative Analysis by Late Stage Development, H1 2013 51
Comparative Analysis by Mid Clinical Stage Development, H1 2013 52
Comparative Analysis by Early Clinical Stage Development, H1 2013 53
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 54
Products under Development by Companies, H1 2013 55
Products under Development by Companies, H1 2013 (Contd..1) 56
Products under Development by Companies, H1 2013 (Contd..2) 57
Products under Development by Companies, H1 2013 (Contd..3) 58
Products under Development by Companies, H1 2013 (Contd..4) 59
Products under Development by Companies, H1 2013 (Contd..5) 60
Products under Development by Companies, H1 2013 (Contd..6) 61
Products under Development by Companies, H1 2013 (Contd..7) 62
Products under Development by Companies, H1 2013 (Contd..8) 63
Products under Development by Companies, H1 2013 (Contd..9) 64
Products under Development by Companies, H1 2013 (Contd..10) 65
Products under Development by Companies, H1 2013 (Contd..11) 66
Products under Development by Companies, H1 2013 (Contd..12) 67
Products under Development by Companies, H1 2013 (Contd..13) 68
Products under Development by Companies, H1 2013 (Contd..14) 69
Products under Development by Companies, H1 2013 (Contd..15) 70
Products under Development by Companies, H1 2013 (Contd..16) 71
Products under Development by Companies, H1 2013 (Contd..17) 72
Products under Development by Companies, H1 2013 (Contd..18) 73
Products under Development by Companies, H1 2013 (Contd..19) 74
Products under Development by Companies, H1 2013 (Contd..20) 75
Products under Development by Companies, H1 2013 (Contd..21) 76
Products under Development by Companies, H1 2013 (Contd..22) 77
Products under Development by Companies, H1 2013 (Contd..23) 78
Products under Development by Companies, H1 2013 (Contd..24) 79
Products under Development by Companies, H1 2013 (Contd..25) 80
Products under Development by Companies, H1 2013 (Contd..26) 81
Products under Development by Companies, H1 2013 (Contd..27) 82
Products under Development by Companies, H1 2013 (Contd..28) 83
Products under Development by Companies, H1 2013 (Contd..29) 84
Products under Investigation by Universities/Institutes, H1 2013 85
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 86
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 87
Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 88
Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 89
Products under Investigation by Universities/Institutes, H1 2013 (Contd..5) 90
Bristol-Myers Squibb Company, H1 2013 91
Aastrom Biosciences, Inc., H1 2013 92
Cardium Therapeutics, Inc., H1 2013 93
Baxter International Inc., H1 2013 94
Johnson and Johnson, H1 2013 95
Boehringer Ingelheim GmbH, H1 2013 96
F. Hoffmann-La Roche Ltd., H1 2013 97
OXIS International, Inc., H1 2013 99
Medinox, Inc., H1 2013 100
Amgen Inc., H1 2013 101
Sanofi-Aventis, H1 2013 102
AstraZeneca PLC, H1 2013 103
Eli Lilly and Company, H1 2013 104
Athersys, Inc., H1 2013 105
GlaxoSmithKline plc, H1 2013 106
Genentech, Inc., H1 2013 107
Sangart, Inc., H1 2013 108
Isis Pharmaceuticals, Inc., H1 2013 109
Gilead Sciences, Inc., H1 2013 110
Daiichi Sankyo Company, Ltd, H1 2013 111
Merck and Co., Inc., H1 2013 112
Nissan Chemical Industries, Ltd., H1 2013 113
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 114
Sangamo BioSciences, Inc., H1 2013 115
Bioheart, Inc., H1 2013 116
Generex Biotechnology Corporation, H1 2013 117
CardioVascular BioTherapeutics, Inc., H1 2013 118
BioLineRx, Ltd., H1 2013 119
Meytav Technological Incubator, H1 2013 120
Reliance Life Sciences Pvt. Ltd., H1 2013 121
BioSante Pharmaceuticals, Inc., H1 2013 122
Neurocrine Biosciences, Inc., H1 2013 123
Novartis AG, H1 2013 124
Isotechnika Pharma Inc., H1 2013 125
Acorda Therapeutics, Inc., H1 2013 126
Actelion Ltd, H1 2013 127
Dong-A Pharmaceutical Co., Ltd., H1 2013 128
Dr. Reddy's Laboratories Limited, H1 2013 129
Forest Laboratories, Inc., H1 2013 130
Glenmark Pharmaceuticals Ltd., H1 2013 131
Kowa Company, Ltd., H1 2013 132
Laboratoires Pierre Fabre SA, H1 2013 133
Les Laboratoires Servier, H1 2013 134
Pfizer Inc., H1 2013 135
Rigel Pharmaceuticals, Inc., H1 2013 136
Sigma-Tau S.p.A., H1 2013 137
Teva Pharmaceutical Industries Limited, H1 2013 138
Zydus Cadila Healthcare Limited, H1 2013 139
Celgene Corporation, H1 2013 140
Shire Plc, H1 2013 141
Bayer AG, H1 2013 142
Celladon Corporation, H1 2013 143
Momenta Pharmaceuticals, Inc., H1 2013 144
IntelGenx Technologies Corp., H1 2013 145
Genfit, H1 2013 146
Medicure Inc., H1 2013 147
Mesoblast Ltd, H1 2013 148
PROLOR Biotech, Inc., H1 2013 149
Nile Therapeutics, Inc., H1 2013 150
NPS Pharmaceuticals, Inc., H1 2013 151
Palatin Technologies, Inc., H1 2013 152
ConjuChem Biotechnologies Inc., H1 2013 153
Cardio3 BioSciences SA, H1 2013 154
La Jolla Pharmaceutical Company, H1 2013 155
Arena Pharmaceuticals, Inc., H1 2013 156
Cardiome Pharma Corp, H1 2013 157
ADVENTRX Pharmaceuticals, H1 2013 158
Portola Pharmaceuticals, Inc., H1 2013 159
CSL Limited, H1 2013 160
Cytokinetics, Inc, H1 2013 161
Yuhan Corporation, H1 2013 162
Anagen Therapeutics, Inc., H1 2013 163
Emisphere Technologies, Inc., H1 2013 164
Proteonomix, Inc., H1 2013 165
Cytomedix, Inc., H1 2013 166
POZEN Inc., H1 2013 167
Arteriocyte, Inc., H1 2013 168
XOMA Ltd., H1 2013 169
ReNeuron Group plc, H1 2013 170
Torrent Pharmaceuticals Limited, H1 2013 171
KunWha Pharmaceutical Co., Ltd., H1 2013 172
Green Cross Corporation, H1 2013 173
Hanall Pharmaceutical Co., Ltd., H1 2013 174
Cytos Biotechnology AG, H1 2013 175
Ahn-Gook Pharmaceutical Co., Ltd., H1 2013 176
LG Life Sciences, Ltd, H1 2013 177
AnGes MG, Inc., H1 2013 178
Pluristem Therapeutics Inc., H1 2013 179
Resverlogix Corp., H1 2013 180
LTT Bio-Pharma Co., Ltd., H1 2013 181
CytoTools AG, H1 2013 182
Pronova BioPharma ASA, H1 2013 183
Simcere Pharmaceutical Group, H1 2013 184
MetrioPharm AG, H1 2013 185
Hybrigenics S.A., H1 2013 186
NeuroVive Pharmaceutical AB, H1 2013 187
Merrion Pharmaceuticals Plc, H1 2013 188
AcelleRX Therapeutics Inc., H1 2013 189
Angelini Group, H1 2013 190
AFFiRiS AG, H1 2013 191
Auspex Pharmaceuticals, H1 2013 192
SCYNEXIS, Inc., H1 2013 193
VistaGen Therapeutics , Inc., H1 2013 194
Chipscreen Biosciences Ltd, H1 2013 195
Viron Therapeutics, Inc., H1 2013 196
Jenrin Discovery, Inc., H1 2013 197
Molecular Partners AG, H1 2013 198
t2cure GmbH, H1 2013 199

List of Figures

Number of Products under Development for Cardiovascular Disease, H1 2013 23
Products under Development for Cardiovascular Disease - Comparative Analysis, H1 2013 24
Products under Development by Companies, H1 2013 25
Products under Investigation by Universities/Institutes, H1 2013 45
Late Stage Products, H1 2013 51
Mid Clinical Stage Products, H1 2013 52
Early Clinical Stage Products, H1 2013 53
Discovery and Pre-Clinical Stage Products, H1 2013 54
Assessment by Monotherapy Products, H1 2013 300
Assessment by Combination Products, H1 2013 301
Assessment by Route of Administration, H1 2013 302
Assessment by Stage and Route of Administration, H1 2013 303
Assessment by Molecule Type, H1 2013 305
Assessment by Stage and Molecule Type, H1 2013 306

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.